Aclaris therapeutics reports q3 loss per share of $1.34

Aclaris therapeutics reports third quarter 2019 financial results and provides business highlights and an update on research and development programs.qtrly loss per share $1.34.as of september 30, 2019, aclaris had aggregate cash, cash equivalents and marketable securities of $91.4 million.q3 revenue $1.0 million.

ACRS Ratings Summary

ACRS Quant Ranking